HighTower Advisors’s Verve Therapeutics VERV Stock Holding History

HighTower Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,237	Closed	-$227K	–	4073
2025 Q2	$227K	Sell	20,237 -1,361	-6%	-$7.76K	﹤0.01%	3176
2025 Q1	$98.7K	Buy	21,598 +1,170	+6%	+$7.84K	﹤0.01%	3358
2024 Q4	$115K	Buy	+20,428	New	+$115K	﹤0.01%	3348
2024 Q1	–	Sell	-15,698	Closed	-$218K	–	4033
2023 Q4	$218K	Buy	+15,698	New	+$195K	﹤0.01%	2950
2022 Q3	–	Sell	-12,000	Closed	-$184K	–	3417
2022 Q2	$184K	Buy	+12,000	New	+$186K	﹤0.01%	2656

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HighTower Advisors's VERV Position: Q3 2025 in Review

HighTower Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 20,237 shares — an estimated $227K sold.

HighTower Advisors first reported a position in VERV in Q2 2022 and held it in 5 quarters. The position peaked at $227K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

HighTower Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
HighTower Advisors sold 20,237 Verve Therapeutics shares in Q3 2025, an estimated $227K.
HighTower Advisors first reported a position in Verve Therapeutics in Q2 2022 and held it in 5 quarters.
HighTower Advisors's Verve Therapeutics position peaked at $227K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on HighTower Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.